纷享销客新15分钟-修订过
产品演示（新15分钟）一、定位与核心价值纷享销客是把销售团队装到手机里，通过互联网的方式，并且是员工爱用的方式，对“销售过程”进行随时随地的“即时管理”，从而提升销售业绩。
它主要解决了外勤行为、销售过程、销售协同以及客户资源四个方面的管理难题。
二、手机端（一）第一，外勤行为管理难：国泰基金的田昆田总曾撞到过他的四个业务人员在茶楼打麻将，虽然这是特例，但销售外勤管理确实是好多公司头疼的事。
用纷享，员工到客户那儿可以用手机进行自我主动签到（操作签到），我们的签到地址不能做假，微博微信是可以改的。
（演示拍照）还可以拍一下现场照片，从而以图文并茂的方式确定本次拜访的真实有效，后台有统计，内外考勤的闭环就形成了。
员工到公司会打卡，到客户那里做一个签到也是合情合理的，这不仅能够展现自己的辛苦与风采，更能养成良好的工作习惯，而且员工与公司之间也可以形成一种默契的信任。
（演示发送范围）纷享每一条信息的发送都像邮件一样，想让谁看谁才能看，每个人看到的内容是不一样的。
以上是我们对外勤行为的管理。
（二）第二，销售过程管理难：要想得到好的结果，一定要对过程有一个强有力的把控，否则结果会有些不可靠，等看到结果一切都晚了，有时候结果是令人惋惜的。
日志是最好的销售过程管理方式，也是员工的一种思维训练和良好的工作习惯。
海尔的张瑞敏认为，每天能够总结、计划一下的习惯是非常了不起的，也是清醒工作与糊涂工作的区别，他就是靠一个“日清卡”把海尔做起来的——做到了日事日毕，日清日高。
以往用日志效果不好，是因为写、看、评都不方便，更谈不上大家的协同，最后就成了形式主义。
而纷享的日志：1、写的方便：可以随时随地的写，在地铁上、在公交车上，写总结、写计划、写心得（演示发日志过程“企业文化”）需要谁来点评，选择谁来协同、共享，都是可以自主选择的。
2、看得方便：我们公司创始人罗旭去美国一个月，心里很踏实，每天看一看日志，公司的情况就基本有数了，罗总说，甚至通过心得都能看出员工的状态（点击“日志查看”）。
3、评得方便：及时点评是日志的灵魂，否则，员工既得不到经验上的支持，也得不到精神上的鼓励，写得就没有动力了。
而纷享的日志可以随时随地地点评，形成日志的闭环，日志就写活了。
（从提醒处演示——点评日志，说明可打分；WORD、表格、PPT即点即看）——正因为写、看、评的方便，所以纷享日志可以做到对销售过程的即时管理，而以往我们看到的往往是滞后的、过时的信息，现在科技实现管理与过程的同步。
这不仅仅是快与慢的问题，有时候也是事前与事后的问题。
刚才提到的国泰基金的田昆田总说：“周一给大家开完周会就出差了，在动车上就发现有的人对周会精神理解得不对，几句话就调整过来了，而以往等三、四天回来之后，一切都晚了”。
田总说：“纷享带着我来到了销售的第一现场，把销售管理压向了最前端，使我宝贵的意识与经验能够第一时间传递给大家，从而快速了解情况、及时发现问题、敏捷做出决策。
他说，纷享是对员工最大的关怀，公司了解到你那儿的情况，公司的帮助就能到达你那里。
”4、（员工爱写的日志）：而再好的设想在员工那里推行不下去也是没有任何意义的。
为什么说纷享的日志员工自发地爱写？因为我们采用了互联网的方式，使大家能够围绕日志进行工作的协同、经验的共享以及精神的共勉！（1）XX为什么爱主动地写日志：（手机待办展示——交互日志）XX的日志已经不再是传统意义上的日志了，XX事需要XX来做，只需要发一篇日志，@某某……这些事自己就在运转了，他第二天出去，路上都能看到结果，都能交互。
他突然发现，再也不用一一给这些人打电话了，更不用把这些人叫到一起开会了，因为许多事情不是一对一能解决的。
当这种多对多的沟通方式一旦转移到企业端的时候，我们的工作方式就发生了一场变革，信息链路打通之后，会使我们的团队变得非常的敏捷。
我们有个客户，郑州最大的牛肉食品商伊赛牛肉买总说：我每天的日志，等同与第二天的工作布署与安排，纷享销客全新日志，是驱动公司及每个人工作的“引擎”与“马达”。
当大家发现，全员都在围绕着他的日志在帮他，日志自然就写起来了，泸州老窖、隆鑫化妆品原来日志都是没写起来的，用纷享很快就写起来了。
员工爱写，我们就实现了对销售过程的即时管理，从而防止结果的失控。
（2）我们再来看看下面这些人为什么爱写日志：A、朱林，入职一个月破零，他在当天把他所有的感受和喜悦都写了出来，因为他想分享，他想展示自我，这里一共有25个赞，23个回复；B、姜雪，她的总监周五的时候让大家写周总结，她在日志里说，白哥，我今天还写不了周总结，因为我的一周还没结束。
为什么呢？因为她想夺销冠，所以她周六周日还想去拜访客户，大家看到后，一片点赞，同时还有人问她如何获得了206个新客户的联系方式。
这也是大家爱写日志的另一个重要原因，因为大家想分享、想交流、想展现自我、想实现存在感。
这就是互联网给我们带来的全新的工作方式，正如伊赛牛肉的买总说：“我们各地的销售两三个月才聚到一起开一个会，这是远远不够的，A的成功经验B还不知道，B犯的错误C还在犯，一个新员工也无法快速融入与成长。
现在用纷享，大家可以天天在一起。
”用纷享，团队可以在第一时间共享经验与精神，在路灯效应下，正能量将会迅速传播，负能量再也没有容身之地；员工之间也会更有归属感和凝聚力。
以上就是我们对销售过程的即时管理。
（三）第三，销售协同管理难1、协同之指令：（演示指令）这是一个极重要的事情才使用的功能。
什么事情，需要谁来做，什么时间完成，需要谁来协同，谁来督导，发出后开始进入倒计时提醒——请给我结果！只有当所有相关人员提交了结果并且由领导点评后提醒才会消失，办不了也给我个说法——这就形成了责任的闭环管理。
搜狐焦点的朱总说：我现在许多重要的事情再也不会因为双方所谓的忙而不了了之，许多战略性的事务都是这样被延误甚至推拖的。
2、协同之审批：（演示三地两级快速交互审批）审批是效率的管理。
北京、上海、深圳三地两级审批10分钟搞定，公司的信息流被加速了。
平台永久留痕留据。
搜狐的朱总说：“我现在再也不是公司效率的最大堵点了，再也不必花钱请人等我了，合同都等丢了，再也不用把那么多宝贵的时间浪费在上传下达的无效环节了。
”这不仅是是与否的问题，围绕着审批，所有相关人员已经在进行沟通和运转了，即严谨又灵活又高效。
这才是现代级审批。
——以上是我们的协同管理，解决的是执行力与效率的问题。
（四）第四管，客户资源管理难客户资源是一个公司的命脉1、我们可以做到把客户资源公司化，企业化。
（1）首先名片管理的混乱是个大问题，甚至都找不到了，但大家又不爱对复杂的信息进行录入。
用纷享，我们可以通过一拍即存的方式进行录入，自动存入公司平台，甚至名片都拍下来了（查看名片）。
员工爱用，我们就实现客户资料的企业化，并且满足客户报备的需要。
（2）（展示一个客户的充分记录）对于一个离职员工来说，他带走的不仅仅是客户的联系方式，更为宝贵的是与客户的所有沟通过程——谁起了决定性作用，新的签约机会又在哪里？隆鑫化妆品的张总说：“我们至少有30%的老客户再次成交机会就这样被白白地带走了，而交接往往是不充分，一般都是带到竞争对手那里去了。
而现在，用纷享，员工甚至可以用语音随时轻松记录、管理自己与客户的沟通过程。
员工爱用，谁不爱管理自己的客户呢？同时也实现了公司最宝贵资源的可沉淀、可承接。
2、动态CRM：领导可以透视下属的客户，从而实现在线即时指导，我甚至可以关注某些重点客户，有任何新的沟通填上来，都会第一时间提醒我，我们围绕着客户又在进行交流，这又是一种变革，所以我们做到了对客户资源动态的、即时的管理。
（展现我对下属客户的多次交互指导）3、打通：纷享是行业内首次打通了工作管理与客户管理两个部分，任何一次签到、日志等工作，都可以关联某个客户，这些碎片化发生的沟通与服务信息，都会被自动归档到客户名下，系统地沉淀下来（展示一个例子），从而解决CRM录入难的问题。
谁不想管理自己的客户呢？但一个人一天围绕4个客户做了12件事，晚上你让他录入，他是录不进去的。
纷享旨在打造大家能够真正的用起来信息化。
（五）除了上述四个管理，我们还有一个即时通讯——企业微信1、我们是企业专属的微信。
我们的体验跟微信一样，但我们都是公司的人，公司的事儿，可以立即相应，不会像微信一样公私不分，无法及时回复；（说一句语音）2、我们企业微信与电脑端是打通的，是有后台、可管理的微信，而且信息会存留在企业里，不再散落于个人手机端；3、我们的企业微信还能即时地收发、查阅文件，不需要下载，即点即看（现场传一个文件，并打开）。
我们打通了电脑与手机端的文件系统，可以做到信息的即时同步。
微信是很好的即时通讯工具，但它没有组织架构、业务流程、业务分类，不能留档查询，而我们是专属的企业级管理工具，当然，企信只是我们即时通讯的一个小功能，我们整体上来说，还是一个系统。
（六）发分享：同时，纷享也是一个大的信息交流平台，员工有任何经验和问题，都可以通过“发分享”来进行即时交流，甚至可以以话题的形式自动分类归档留存。
比如这样一个群策群利话题，我们当天晚上就完成了对一次不成功会议的充分总结，这就是互联网给我们带来的全新的工作方式。
——手机端总结：以上就是我们纷享销客的手机端，主要对于销售的外勤、过程、协同以及客户资源四个核心环节进行管理，同时也是一个即时通讯和大的信息分享平台。
原来在外面，大家的事都压在手里、压在心里，现在我们随手就都办了，碎片化时间移动办公是未来不可逆转的大趋势。
三、电脑——转折语：下面，我再给你介绍一下电脑端的统计管理功能。
1、手机上的企业微信与电脑同步（播放刚才发的语音）。
2、（展示一个人签到地图）何时何地做何事，通过签到，我们可以知道一个员工的外勤签到，以及客户分布，以便于今后工作的开展，比如集中广告，集中宣传等。
3、我们还有日志导出表，日志统计表，审批统计表，请假统计表等，还可以看一个人的工作效能，我们甚至节省了您的人工。
（查看个人统计信息，说明某个领导的审批效率不超过30分钟）。
四、总结我们实际上是把每一个员工的手机都变成了一个时时在线的工作终端，把销售外勤、过程、协同、以及客户资源这四个管理核心环节轻松地融合在一部手机之中，从而进行即时沟通、实时管理。
员工可随时便捷地工作，管理者也可以随时俯瞰公司，离场管理。
并且通过互联网的方式，打破时间与空间的局限，真正地把您的公司装到手机里，大家像每天在一起工作一样，做到充分的信息对称，实现扁平化管理。
从而使团队变得更轻、更快、更敏捷！同时，提高效率与执行力！对于员工来说，纷享又是一个轻松、高效、能得到更多支持与智慧、更多签单的平台，大家在一起工作更开心，从而提升了团队的活力、创造力与凝聚力！用纷享，人在一起，心在一起，智慧在一起。
纷享销客「移动中的销售管理
纷享销客「移动中的销售管理“我认识的一个老板都快得神经衰弱了。
”吴昊眼中的这位老板白天忙着应酬，晚上才有时间在电脑的OA 系统上处理文件，而他手下员工能做的只能是等待批复，工作进程常常阻滞。
作为纷享销客的副总裁，吴昊开始思考，这样的生活节奏是领导们想要的吗？这样的工作方式是销售人员想要的吗？我们的网络变快了，时间却变散了。
正如纷享销客的创始人兼CEO罗旭所说，“人们大量的时间是在路上”。
随着4G和智能手机的普及，碎片化的娱乐已被人们广为接受，但碎片化的办公理念仍处于发展阶段，不过这并不意味着市场没有需求。
当职场85后、90后新生代涌入，他们从小就习惯并熟知网络、手机等移动工具，他们渴望自由的生活和工作方式，因此他们也将更容易适应和需要移动办公。
随着云服务的兴起，移动互联网与智能终端的普及，使用户效率提升的需求以及碎片化时间的有效利用等行为发生了巨大变化，碎片化时代的来临，终将优化我们的传统办公理念，也将解放吴昊眼中的那位神经衰弱的老板。
专注销售管理让老板和员工都自由在这场移动终端刮起的“风暴”中，国外的Yammer、Salesforce等新型的企业管理和沟通软件应运而生。
微软以12亿美元的价格收购Yammer；成功上市的Salesforce，市值已达340亿美元。
与此同时，Dropbox、Evernote等消费市场软件，也在积极开拓企业市场，推出其企业版本和服务。
手机应用不再只是2C的天下，2B应用开始走进大众的视线。
构建以人为核心、以业务为驱动的柔性SAAS服务平台，将产品、服务、平台、资源聚合为一体，为企业提供软件服务、大数据分析与社会化资源整合，正在成为未来软件级企业的发展方向。
纷享销客就是一款集易用性、必要性、高效性、移动性于一身的企业级销售管理软件。
纷享销客创新地将客户信息、服务轨迹和销售分析通过移动端进行实时更新和展现，本质是专注于销售团队、销售能力与客户资源的管理。
企业中常常令人头疼的问题是：老板经常不知道自己的业务员去哪儿了，而业务员也经常需要为得到老板的审批而长途跋涉地赶回办公室，类似的情况在销售团队中是家常便饭。
纷享销客财务报告分析(3篇)
第1篇摘要：纷享销客作为中国领先的移动办公和客户关系管理（CRM）服务商，近年来在市场竞争中表现出色，实现了稳健的业绩增长。
本文通过对纷享销客财务报告的深入分析，旨在揭示其财务状况、盈利能力、运营效率和市场竞争力，为投资者和利益相关者提供决策参考。
一、财务概况1. 营业收入纷享销客营业收入在近年来呈现稳定增长趋势。
根据财务报告显示，2022年营业收入为XX亿元，较2021年增长XX%。
这表明公司在市场竞争中具有较强的盈利能力。
2. 净利润纷享销客净利润在2022年达到XX亿元，较2021年增长XX%。
净利润的增长主要得益于公司产品线的丰富、客户群体的扩大以及运营效率的提升。
3. 毛利率纷享销客毛利率在2022年达到XX%，较2021年略有下降。
这主要由于市场竞争加剧，公司为了保持市场竞争力，对部分产品进行了降价策略。
但整体来看，公司毛利率仍处于行业较高水平。
4. 净资产收益率纷享销客净资产收益率在2022年达到XX%，较2021年略有上升。
这表明公司利用自有资金创造利润的能力较强。
二、盈利能力分析1. 产品盈利能力纷享销客主要产品包括移动办公平台、CRM系统等。
根据财务报告显示，移动办公平台和CRM系统的毛利率分别为XX%和XX%，表明公司产品具有较强的盈利能力。
2. 市场占有率纷享销客在移动办公和CRM领域具有较高的市场占有率。
根据相关数据，公司市场份额在2022年达到XX%，较2021年增长XX%。
这主要得益于公司产品在功能、性能和用户体验方面的优势。
三、运营效率分析1. 应收账款周转率纷享销客应收账款周转率在2022年为XX次，较2021年略有下降。
这表明公司在应收账款管理方面仍需加强。
2. 存货周转率纷享销客存货周转率在2022年为XX次，较2021年有所提高。
这主要得益于公司优化了库存管理，提高了存货周转效率。
3. 销售费用率纷享销客销售费用率在2022年为XX%，较2021年略有上升。
咖啡因工艺规程
目录一、产品概述 (1)二、原辅材料、包装材料规格及标准 (3)三、化学反应过程及生产流程图 (4)四、工艺过程 (9)五、生产工艺和质量控制检查、中间体和成品质量标准 (18)六、技术安全与防火 (20)七、综合利用与“三废”治理 (32)八、操作工时与生产周期 (34)九、劳动组织与岗位定员 (35)十、设备一览表及主要设备生产能力 (36)十一、原材料、动力消耗定额和技术经济指标 (43)十二、物料平衡 (45)十三、附录 (48)十四、附页 (50)咖啡因工艺规程一、 产品名称及概述（一）产品名称[通用名称] 咖啡因，亦称咖啡碱[化学名称] 1，3，7-一三甲基-3,7-二氢-1H-嘌呤-2，6-二酮。
[英文名称] Caffeine （二） 化学结构式·H 2O无水咖啡因 含水咖啡因 （三）分子式与分子量无水咖啡因 C 8H 10N 4O 2 194.19 含水咖啡因 C 8H 10N 4O 2·H 2O 212.21 (四) 理化性质[外观] 含水咖啡因为白色或带极微黄绿色有丝光的针状结晶或粉末，无水咖啡因为白色或带极微黄色的结晶或粉末。
[味道] 无臭，味苦。
[溶解度]在热水或氯仿中易溶，在水、乙醇或丙酮中略溶，在乙醚中微溶。
水20℃（1：60），80℃（1：6）。
乙醇（1：26），60℃（1：25）。
丙酮（1：80）。
乙醚（1：60）。
氯仿（1：6）。
[风化性与升华性现象] 本品在热水中重结晶为含1分子水的结晶。
露置于干燥空气中能失去部分结晶水，受热后（常压下100℃）可完全失去结晶水而成无水咖啡因，具风化性；本品在100℃时即有升华现象，一般在130℃-200℃范围内升华，180℃升华最快，384℃部分分解。
[熔点] 234-239℃。
NN NOH 3CCH 33O NN NOH 3CCH 33O[酸碱性] 本品1%水溶液pH=5.5-6.9。
咖啡因的碱性依次大于可可豆碱（3，7-二甲基黄嘌呤）和茶碱，但其碱性仍极弱，不易和酸结合成盐，即使成盐（例如它的盐酸盐）也极不稳定，溶于水或醇中立即分解又转变为游离咖啡因和酸。
纷享销客审批流程
关于各项费用申请及纷享销客流程
1、借款单、付款申请单、差旅费报销单、原始凭证汇总单纸质审批：
经办人→部门负责人→财务总监→校长完成→上传纷享销客→董事长审批（抄送部门见下图）；
2、纷享销客流程：
经办人→部门负责人→财务总监→校长→董事长审批
3、报送纷享销客审批时需要上传各页材料，并说明各项支出情况。
借款单、付款申请单、差旅费报销单、原始凭证汇总单纸质填写好，不定期的带回总部，由财务人员找责任人审批补签。
纷享销客审批流程
出差申请、加班申请、请假申请、公章使用申请、退学（休学）申请单等其他申请仍按照原规定纷享销客逐级申请。
20**年7月7日。
纷享销客产品(销售版)
▲ 比对点评，及时指导
手机提交，移动查阅
▲
日志日历，点击查看，构建工作档案馆
▲
日历导出，便于工作复盘分析
▲
客户资源管理：移动CRM
以客户为中心”将是CRM的核心所在---任何企业实施客户关系管理的初 衷都是想为顾客创造更多的价值，即实现顾客与企业的“双赢”。
客户管理
名片扫描 销售笔记 信息透视
销售日志管理 在做什么？ 如何做复盘？
客户资源管理 客户如何沉淀？ 业务如何预测？
销售协同管理 支持够不够？ 团队配合如何？
行为决定作为
销售外勤管理：手机LBS签到
▲地图定位
▲现场拍照
▲发至平台
签到数据导出，便于考勤统计
客户拜访效率
▲
销售网点布局 拜访线路优化
▲ ▲
过程成就结果
销售日志管理：专属销售日志
扫描二维码下载手机客户端
苹果手机
安卓手机
北京市海淀区知春路甲63号卫星大厦7层 官网： / 服务热线：4006689050 / 扫描关注官方微信：
打单 但不单打
销售协同管理：审批、指令、企信…
知识分享
文档网盘
▲
Hale Waihona Puke ▲▲企业微信
移动审批
任务指令
互动日程
▲
公告
……
移动 易用 高效
有5亿人在用微博 有6亿人在用微信
截止2014.12，超过70000家 企业选择使用纷享销客。
编写短信内容“纷享销客” 发送至12114，即获手机客 户端下载链接。
的机会管理帮助企业实 现销售自动化。
合同与回款管理：
签约-回款-售后服务，移
动合同管理帮您随时了解
销售易与纷享销客功能对比-销售漏斗
销售易与纷享销客功能对比-销售漏斗1.销售漏斗是什么？销售漏斗是所有CRM产品必备的基础功能，一个好的销售漏斗工具，可以指导销售人员如何去推进项目，更可以帮助管理层了解销售业务的状态、定位发展瓶颈。
2.纷享销客的产品图 1.纷享销客的销售阶段划分如图1所示，纷享销客的商机阶段变化，依靠手动修改，随意性强、主观影响大。
销售人员胡乱填写，今天是“初步拜访”明天就是“商务谈判”，这样又怎么能进行准确的销售管理和业绩预测呢？图 2.纷享销客的销售漏斗功能纷享销客的销售漏斗（图2）是一张根据数据生成的静态图片，无法进一步查看细节。
即没有每个阶段包含的项目信息，也无法展示流失率、留存率等数据。
对管理层起不到任何指导作用，虚有其表。
3.销售易的产品作为业内公认的“最创新的技术、最专业的产品”的销售易CRM，是如何让销售漏斗功能真正发挥价值的呢？图 3.销售易的销售阶段划分和关键任务设置销售易CRM为不同的销售阶段设定关键任务（图3），解答销售人员“现在我该干什么”的疑问。
逐项排查、准确引导、快速突破。
让每一个项目都按照最恰当的销售流程推进；关键任务不完成，无法进到下一阶段，减少了销售人员主观因素造成的误判。
业绩预测更准确。
图 4.销售易的销售漏斗和相关项目详情通过销售易的销售漏斗（图4），您可以详细查看每个阶段有哪些商机、重点项目的进展情况如何，每个项目金额有多大，想看哪里点哪里。
通过一个工具，就能让管理者洞悉业务发展的细节。
图 5.销售易的销售漏斗流失率、滞留率和升迁率商机在销售漏斗不同阶段的升迁率、流失率和滞留率，能够帮助管理者及时管理和预测销售业绩、形成标准方法论、定位问题并提供有针对性的指导。
“初步接触”阶段的商机较少，说明需要加强市场宣传、更多的获取商机；“报价提交”阶段的流失率较高，说明我们需要调整产品价格。
销售易CRM帮你挖掘这些藏在数据中的金子，为您日后的企业经营决策提供数据支撑。
上门流程及说辞
一、上门流程约访问（确认上门时间和地点，核对客户资质--①是否为企业，具有营业执照和相关许可证；）上门准备（准备sales kit，填写上门登记表）开场白（我是谁？来干嘛？关你什么事？）话天地（拍马屁、扯淡、了解客户背景，产品、市场范围及销售渠道、是否有网络意识、是否KP）挖需求（多问少说）入主题（用FABE法则<特征、优势、利益、成功案例>，结合客户最关心的四个问题<客户群、竞争对手、自己的产品、成功同行>来介绍服务）上网演示（下载客户端，通过电脑操作公司账号，演示如何定位签到，如何通过日志管理、如何通过审批、指令提升工作效率等等）试缔结（试探客户对价格的接受度和意向度）介绍收费包（通用报价表方案）促销紧迫感营造（打配合电话确认客户意向）签单收款走人（未收到约定下次拜访、收到约定培训时间）二、上门说辞开场白参考说辞：Y总您好，我是“纷享销客”的客户经理，昨天下午（时间）约了今天过来拜访您，就纷享销客进行具体沟通和演示。
话天地参考说辞：Y总，您这办公室装修的真有格调，现在我们公司生意应该是做的不错的吧，经营这块业务做了多少年了？我看过很多你们行业的客户，你们这个规模已经非常大了。
我们现在主要通过什么方式来管理外勤员工，管理老客户呢？挖需求Y总，您知道贵公司外勤人员平常去哪了，拜访效率如何吗？能否了解员工平常在做什么，如何跟踪客户的吗？每天的工作汇报方不方便？如何对客户进行管理？公司给的支持够不够，团队配合如何？入主题5大卖点，结合15分钟话术，内容会说会演会包装上网演示1、下载客户端，登陆公司电脑操作公司账号；2、演示如何“签到”3、演示‘日志管理-写、看、评、互动等’4、如何通过审批、指令提升团队协作力5、如何运用CRM管理客户6、企业微信试缔结1、今天服务和产品已经很了解了，纷享销客现在开发市场，现在很多人也在使用，要不Y总我们一起来看下合同，同时我给您确认一下目前的优惠。
FDA-伏立康唑说明书
VFEND® I.V.(voriconazole) for InjectionVFEND® Tablets(voriconazole)VFEND®(voriconazole) for Oral SuspensionDESCRIPTIONVFEND® (voriconazole), a triazole antifungal agent, is available as a lyophilized powder for solution for intravenous infusion, film-coated tablets for oral administration, and as a powder for oral suspension. The structural formula is:Voriconazole is designated chemically as (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol with an empirical formula of C16H14F3N5O and a molecular weight of 349.3.Voriconazole drug substance is a white to light-colored powder.VFEND I.V. is a white lyophilized powder containing nominally 200 mg voriconazole and 3200 mg sulfobutyl ether beta-cyclodextrin sodium in a 30 mL Type I clear glass vial.VFEND I.V. is intended for administration by intravenous infusion. It is a single-dose, unpreserved product. Vials containing 200 mg lyophilized voriconazole are intended for reconstitution with Water for Injection to produce a solution containing 10 mg/mL VFEND and 160 mg/mL of sulfobutyl ether beta-cyclodextrin sodium. The resultant solution is further diluted prior to administration as an intravenous infusion (see DOSAGE AND ADMINISTRATION). VFEND Tablets contain 50 mg or 200 mg of voriconazole. The inactive ingredients include lactose monohydrate, pregelatinized starch, croscarmellose sodium, povidone, magnesiumstearate and a coating containing hypromellose, titanium dioxide, lactose monohydrate and triacetin.VFEND for Oral Suspension is a white to off-white powder providing a white to off-white orange-flavored suspension when reconstituted. Bottles containing 45 g powder for oral suspension are intended for reconstitution with water to produce a suspension containing 40mg/mL voriconazole. The inactive ingredients include colloidal silicon dioxide, titanium dioxide, xanthan gum, sodium citrate dihydrate, sodium benzoate, anhydrous citric acid, natural orange flavor, and sucrose.CLINICAL PHARMACOLOGYPharmacokineticsGeneral Pharmacokinetic CharacteristicsThe pharmacokinetics of voriconazole have been characterized in healthy subjects, special populations and patients.The pharmacokinetics of voriconazole are non-linear due to saturation of its metabolism. The interindividual variability of voriconazole pharmacokinetics is high. Greater than proportional increase in exposure is observed with increasing dose. It is estimated that, on average, increasing the oral dose in healthy subjects from 200 mg Q12h to 300 mg Q12h leads to a 2.5-fold increase in exposure (AUCτ), while increasing the intravenous dose from 3 mg/kg Q12h to 4 mg/kg Q12h produces a 2.3-fold increase in exposure (Table 1).Table 1Population Pharmacokinetic Parameters of Voriconazole in Subjects200 mg Oral Q12h 300 mg Oral Q12h 3 mg/kg IV Q12h 4 mg/kg IV Q12hAUCτ* (μg•h/mL) (CV%) 19.86(94%)50.32(74%)21.81(100%)50.40(83%)*Mean AUCτ are predicted values from population pharmacokinetic analysis of data from 236 subjectsDuring oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or hematopoietic tissue), the observed pharmacokinetic characteristics were similar to those observed in healthy subjects (Table 2).Table 2Pharmacokinetic Parameters of Voriconazole in Patients at Risk for Aspergillosis200 mg Oral Q12h(n=9) 300 mg Oral Q12h(n=9)AUCτ* (μg•h/mL ) (CV%) 20.31(69%)36.51(45%)C max* (μg/mL) (CV%) 3.00(51%)4.66(35%)*Geometric mean values on Day 14 of multiple dosing in 2 cohorts of patientsSparse plasma sampling for pharmacokinetics was conducted in the therapeutic studies in patients aged 12-18 years. In 11 adolescent patients who received a mean voriconazole maintenance dose of 4 mg/kg IV, the median of the calculated mean plasma concentrations was 1.60 μg/mL (inter-quartile range 0.28 to 2.73 μg/mL).In 17 adolescent patients for whom mean plasma concentrations were calculated following a mean oral maintenance dose of 200 mg Q12h, the median of the calculated mean plasma concentrations was 1.16 μg/mL (inter-quartile range 0.85 to 2.14 μg/mL).When the recommended intravenous or oral loading dose regimens are administered to healthy subjects, peak plasma concentrations close to steady state are achieved within the first 24 hours of dosing. Without the loading dose, accumulation occurs during twice-daily multiple dosing with steady-state peak plasma voriconazole concentrations being achieved by day 6 in the majority of subjects (Table 3).Table 3Pharmacokinetic Parameters of Voriconazole from Loading Dose and Maintenance Dose Regimens(Individual Studies in Subjects)400 mg Q12h on Day 1, 200 mg Q12h on Days 2 to 10(n=17)6 mg/kg IV** Q12h on Day 1, 3 mg/kg IV Q12h on Days 2 to 10(n=9)Day 1, 1st dose Day 10 Day 1, 1st dose Day 10AUCτ* (μg•h/mL) (CV%) 9.31(38%)11.13(103%)13.22(22%)13.25(58%)C max (μg/mL) (CV%) 2.30(19%)2.08(62%)4.70(22%)3.06(31%)*AUCτ values are calculated over dosing interval of 12 hoursPharmacokinetic parameters for loading and maintenance doses summarized for same cohort of subjects**IV infusion over 60 minutesSteady state trough plasma concentrations with voriconazole are achieved after approximately 5 days of oral or intravenous dosing without a loading dose regimen. However, when an intravenous loading dose regimen is used, steady state trough plasma concentrations are achieved within 1 day.AbsorptionThe pharmacokinetic properties of voriconazole are similar following administration by the intravenous and oral routes. Based on a population pharmacokinetic analysis of pooled data in healthy subjects (N=207), the oral bioavailability of voriconazole is estimated to be 96% (CV 13%). Bioequivalence was established between the 200 mg tablet and the 40 mg/mL oral suspension when administered as a 400 mg Q12h loading dose followed by a 200 mg Q12h maintenance dose.Maximum plasma concentrations (C max) are achieved 1-2 hours after dosing. When multiple doses of voriconazole are administered with high-fat meals, the mean C max and AUCτ are reduced by 34% and 24%, respectively when administered as a tablet and by 58% and 37% respectively when administered as the oral suspension (see DOSAGE AND ADMINISTRATION).In healthy subjects, the absorption of voriconazole is not affected by coadministration of oral ranitidine, cimetidine, or omeprazole, drugs that are known to increase gastric pH.DistributionThe volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues. Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 μg/mL). Varying degrees of hepatic and renal insufficiency do not affect the protein binding of voriconazole.MetabolismIn vitro studies showed that voriconazole is metabolized by the human hepatic cytochrome P450 enzymes, CYP2C19, CYP2C9 and CYP3A4 (see CLINICAL PHARMACOLOGY - Drug Interactions).In vivo studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolizers. For Caucasians and Blacks, the prevalence of poor metabolizers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolizers have, on average, 4-fold higher voriconazole exposure (AUCτ) than their homozygous extensive metabolizer counterparts. Subjects who are heterozygous extensive metabolizers have, on average, 2-fold higher voriconazole exposure than their homozygous extensive metabolizer counterparts.The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. Since this metabolite has minimal antifungal activity, it does not contribute to the overall efficacy of voriconazole.ExcretionVoriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine. After administration of a single radiolabelled dose of either oral or IV voriconazole, preceded by multiple oral or IV dosing, approximately 80% to 83% of theradioactivity is recovered in the urine. The majority (>94%) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing.As a result of non-linear pharmacokinetics, the terminal half-life of voriconazole is dose dependent and therefore not useful in predicting the accumulation or elimination of voriconazole.Pharmacokinetic-Pharmacodynamic RelationshipsClinical Efficacy and SafetyIn 10 clinical trials, the median values for the average and maximum voriconazole plasma concentrations in individual patients across these studies (N=1121) was 2.51 μg/mL (inter-quartile range 1.21 to 4.44 μg/mL) and 3.79 μg/mL (inter-quartile range 2.06 to 6.31 μg/mL), respectively. A pharmacokinetic-pharmacodynamic analysis of patient data from 6 of these 10 clinical trials (N=280) could not detect a positive association between mean, maximum or minimum plasma voriconazole concentration and efficacy. However, PK/PD analyses of the data from all 10 clinical trials identified positive associations between plasma voriconazole concentrations and rate of both liver function test abnormalities and visual disturbances (see ADVERSE REACTIONS).ElectrocardiogramA placebo-controlled, randomized, crossover study to evaluate the effect on the QT interval of healthy male and female subjects was conducted with three single oral doses of voriconazole and ketoconazole. Serial ECGs and plasma samples were obtained at specified intervals over a 24-hour post dose observation period. The placebo-adjusted mean maximum increases in QTc from baseline after 800, 1200 and 1600 mg of voriconazole and after ketoconazole 800 mg were all <10 msec. Females exhibited a greater increase in QTc than males, although all mean changes were <10 msec. Age was not found to affect the magnitude of increase in QTc. No subject in any group had an increase in QTc of ≥60 msec from baseline. No subject experienced an interval exceeding the potentially clinically relevant threshold of 500 msec. However, the QT effect of voriconazole combined with drugs known to prolong the QT interval is unknown (see CONTRAINDICATIONS, PRECAUTIONS-Drug Interactions).Pharmacokinetics in Special PopulationsGenderIn a multiple oral dose study, the mean C max and AUCτfor healthy young females were 83% and 113% higher, respectively, than in healthy young males (18-45 years), after tablet dosing. In the same study, no significant differences in the mean C max and AUCτ were observed between healthy elderly males and healthy elderly females (>65 years). In a similar study, after dosing with the oral suspension, the mean AUC for healthy young females was 45% higher than in healthy young males whereas the mean C max was comparable between genders. The steady state trough voriconazole concentrations (C min) seen in females were 100% and 91% higher than in males receiving the tablet and the oral suspension, respectively.In the clinical program, no dosage adjustment was made on the basis of gender. The safety profile and plasma concentrations observed in male and female subjects were similar. Therefore, no dosage adjustment based on gender is necessary.GeriatricIn an oral multiple dose study the mean C max and AUCτin healthy elderly males (≥ 65 years) were 61% and 86% higher, respectively, than in young males (18-45 years). No significant differences in the mean C max and AUCτ were observed between healthy elderly females ( ≥ 65 years) and healthy young females (18-45 years).In the clinical program, no dosage adjustment was made on the basis of age. An analysis of pharmacokinetic data obtained from 552 patients from 10 voriconazole clinical trials showed that the median voriconazole plasma concentrations in the elderly patients (>65 years) were approximately 80% to 90% higher than those in the younger patients (≤65 years) after either IV or oral administration. However, the safety profile of voriconazole in young and elderly subjects was similar and, therefore, no dosage adjustment is necessary for the elderly.PediatricA population pharmacokinetic analysis was conducted on pooled data from 35 immunocompromised pediatric patients aged 2 to <12 years old who were included in two pharmacokinetic studies of intravenous voriconazole (single dose and multiple dose). Twenty-four of these patients received multiple intravenous maintenance doses of 3 mg/kg and 4 mg/kg.A comparison of the pediatric and adult population pharmacokinetic data revealed that the predicted average steady state plasma concentrations were similar at the maintenance dose of 4 mg/kg every 12 hours in children and 3 mg/kg every 12 hours in adults (medians of 1.19 μg/mL and 1.16 μg/mL in children and adults, respectively) (see PRECAUTIONS, Pediatric Use). Hepatic InsufficiencyAfter a single oral dose (200 mg) of voriconazole in 8 patients with mild (Child-Pugh Class A) and 4 patients with moderate (Child-Pugh Class B) hepatic insufficiency, the mean systemic exposure (AUC) was 3.2-fold higher than in age and weight matched controls with normal hepatic function. There was no difference in mean peak plasma concentrations (C max) between the groups. When only the patients with mild (Child-Pugh Class A) hepatic insufficiency were compared to controls, there was still a 2.3-fold increase in the mean AUC in the group with hepatic insufficiency compared to controls.In an oral multiple dose study, AUCτwas similar in 6 subjects with moderate hepatic impairment (Child-Pugh Class B) given a lower maintenance dose of 100 mg twice daily compared to 6 subjects with normal hepatic function given the standard 200 mg twice daily maintenance dose. The mean peak plasma concentrations (C max) were 20% lower in the hepatically impaired group. It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh Class A and B) receiving voriconazole. No pharmacokinetic data are available for patients with severe hepatic cirrhosis (Child-Pugh Class C) (see DOSAGE AND ADMINISTRATION).Renal InsufficiencyIn a single oral dose (200 mg) study in 24 subjects with normal renal function and mild to severe renal impairment, systemic exposure (AUC) and peak plasma concentration (C max) of voriconazole were not significantly affected by renal impairment. Therefore, no adjustment is necessary for oral dosing in patients with mild to severe renal impairment.In a multiple dose study of IV voriconazole (6 mg/kg IV loading dose x 2, then 3 mg/kg IV x 5.5 days) in 7 patients with moderate renal dysfunction (creatinine clearance 30-50 mL/min), the systemic exposure (AUC) and peak plasma concentrations (C max) were not significantly different from those in 6 subjects with normal renal function.However, in patients with moderate renal dysfunction (creatinine clearance 30-50 mL/min), accumulation of the intravenous vehicle, SBECD, occurs. The mean systemic exposure (AUC) and peak plasma concentrations (C max) of SBECD were increased 4-fold and almost 50%, respectively, in the moderately impaired group compared to the normal control group. Intravenous voriconazole should be avoided in patients with moderate or severe renal impairment (creatinine clearance <50 mL/min), unless an assessment of the benefit/risk to the patient justifies the use of intravenous voriconazole (see DOSAGE AND ADMINISTRATION - Dosage Adjustment).A pharmacokinetic study in subjects with renal failure undergoing hemodialysis showed that voriconazole is dialyzed with clearance of 121 mL/min. The intravenous vehicle, SBECD, is hemodialyzed with clearance of 55 mL/min. A 4-hour hemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.Drug InteractionsEffects of Other Drugs on VoriconazoleVoriconazole is metabolized by the human hepatic cytochrome P450 enzymes CYP2C19,CYP2C9, and CYP3A4. Results of in vitro metabolism studies indicate that the affinity of voriconazole is highest for CYP2C19, followed by CYP2C9, and is appreciably lower forCYP3A4. Inhibitors or inducers of these three enzymes may increase or decrease voriconazole systemic exposure (plasma concentrations), respectively.The systemic exposure to voriconazole is significantly reduced or is expected to be reduced by the concomitant administration of the following agents and their use is contraindicated: Rifampin (potent CYP450 inducer): Rifampin (600 mg once daily) decreased the steady state C max and AUCτ of voriconazole (200 mg Q12h x 7 days) by an average of 93% and 96%, respectively, in healthy subjects. Doubling the dose of voriconazole to 400 mg Q12h does not restore adequate exposure to voriconazole during coadministration with rifampin. Coadministration of voriconazole and rifampin is contraindicated (see CONTRAINDICATIONS, PRECAUTIONS - Drug Interactions).Ritonavir (potent CYP450 inducer; CYP3A4 inhibitor and substrate): The effect of the coadministration of voriconazole and ritonavir (400 mg and 100 mg) was investigated in twoseparate studies. High-dose ritonavir (400 mg Q12h for 9 days) decreased the steady state C max and AUCτ of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) by an average of 66% and 82%, respectively, in healthy subjects. Low-dose ritonavir (100 mg Q12h for 9 days) decreased the steady state C max and AUCτ of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) by an average of 24% and 39%, respectively, in healthy subjects. Although repeat oral administration of voriconazole did not have a significant effect on steady state C max and AUCτ of high-dose ritonavir in healthy subjects, steady state C max and AUCτ of low-dose ritonavir decreased slightly by 24% and 14% respectively, when administered concomitantly with oral voriconazole in healthy subjects. Coadministration of voriconazole and high-dose ritonavir (400 mg Q12h) is contraindicated.Coadministration of voriconazole and low-dose ritonavir (100 mg Q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. (see CONTRAINDICATIONS, PRECAUTIONS - Drug Interactions).St. John’s Wort(CYP450 inducer; P-gp inducer): In an independent published study in healthy volunteers who were given multiple oral doses of St. John’s Wort (300 mg LI 160 extract three times daily for 15 days) followed by a single 400 mg oral dose of voriconazole, a 59% decrease in mean voriconazole AUC0-∞was observed. In contrast, coadministration of single oral doses of St. John’s Wort and voriconazole had no appreciable effect on voriconazole AUC0-∞. Because long-term use of St. John’s Wort could lead to reduced voriconazole exposure, concomitant use of voriconazole with St. John’s Wort is contraindicated (see CONTRAINDICATIONS, PRECAUTIONS – Drug Interactions).Carbamazepine and long-acting barbiturates (potent CYP450 inducers): Although not studied in vitro or in vivo, carbamazepine and long-acting barbiturates (e.g., phenobarbital, mephobarbital) are likely to significantly decrease plasma voriconazole concentrations. Coadministration of voriconazole with carbamazepine or long-acting barbiturates is contraindicated (see CONTRAINDICATIONS, PRECAUTIONS - Drug Interactions).Minor or no significant pharmacokinetic interactions that do not require dosage adjustment:Cimetidine (non-specific CYP450 inhibitor and increases gastric pH): Cimetidine (400 mgQ12h x 8 days) increased voriconazole steady state C max and AUCτ by an average of 18% (90% CI: 6%, 32%) and 23% (90% CI: 13%, 33%), respectively, following oral doses of 200 mgQ12h x 7 days to healthy subjects.Ranitidine (increases gastric pH): Ranitidine (150 mg Q12h) had no significant effect on voriconazole C max and AUCτfollowing oral doses of 200 mg Q12h x 7 days to healthy subjects.Macrolide antibiotics: Coadministration of erythromycin (CYP3A4 inhibitor;1g Q12h for 7 days) or azithromycin (500 mg qd for 3 days) with voriconazole 200 mg Q12h for 14 days had no significant effect on voriconazole steady state C max and AUCτ in healthy subjects. The effects of voriconazole on the pharmacokinetics of either erythromycin or azithromycin are not known.Effects of Voriconazole on Other DrugsIn vitro studies with human hepatic microsomes show that voriconazole inhibits the metabolic activity of the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4. In these studies, the inhibition potency of voriconazole for CYP3A4 metabolic activity was significantly less than that of two other azoles, ketoconazole and itraconazole. In vitro studies also show that the major metabolite of voriconazole, voriconazole N-oxide, inhibits the metabolic activity of CYP2C9 and CYP3A4 to a greater extent than that of CYP2C19. Therefore, there is potential for voriconazole and its major metabolite to increase the systemic exposure (plasma concentrations) of other drugs metabolized by these CYP450 enzymes.The systemic exposure of the following drugs is significantly increased or is expected to be significantly increased by coadministration of voriconazole and their use is contraindicated: Sirolimus (CYP3A4 substrate): Repeat dose administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 8 days) increased the C max and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold (90% CI: 9.9, 12.6), respectively, in healthy male subjects. Coadministration of voriconazole and sirolimus is contraindicated (see CONTRAINDICATIONS, PRECAUTIONS - Drug Interactions).Terfenadine, astemizole, cisapride, pimozide and quinidine (CYP3A4 substrates): Although not studied in vitro or in vivo, concomitant administration of voriconazole with terfenadine, astemizole, cisapride, pimozide or quinidine may result in inhibition of the metabolism of these drugs. Increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of torsade de pointes. Coadministration of voriconazole and terfenadine, astemizole, cisapride, pimozide and quinidine is contraindicated (see CONTRAINDICATIONS, PRECAUTIONS - Drug Interactions).Ergot alkaloids: Although not studied in vitro or in vivo, voriconazole may increase the plasma concentration of ergot alkaloids (ergotamine and dihydroergotamine) and lead to ergotism. Coadministration of voriconazole with ergot alkaloids is contraindicated (see CONTRAINDICATIONS, PRECAUTIONS - Drug Interactions).Coadministration of voriconazole with the following agents results in increased exposure or is expected to result in increased exposure to these drugs. Therefore, careful monitoring and/or dosage adjustment of these drugs is needed:Cyclosporine (CYP3A4 substrate): In stable renal transplant recipients receiving chronic cyclosporine therapy, concomitant administration of oral voriconazole (200 mg Q12h for 8 days) increased cyclosporine C max and AUCτ an average of 1.1 times (90% CI: 0.9, 1.41) and 1.7 times (90% CI: 1.5, 2.0), respectively, as compared to when cyclosporine was administered without voriconazole. When initiating therapy with voriconazole in patients already receiving cyclosporine, it is recommended that the cyclosporine dose be reduced to one-half of the original dose and followed with frequent monitoring of the cyclosporine blood levels. Increased cyclosporine levels have been associated with nephrotoxicity. When voriconazole is discontinued, cyclosporine levels should be frequently monitored and the dose increased as necessary (see PRECAUTIONS - Drug Interactions).Methadone (CYP3A4, CYP2C19, CYP2C9 substrate): Repeat dose administration of oral voriconazole (400mg Q12h for 1 day, then 200mg Q12h for 4 days) increased the C max and AUCτ of pharmacologically active R-methadone by 31% (90% CI: 22%, 40%) and 47% (90% CI: 38%, 57%), respectively, in subjects receiving a methadone maintenance dose (30-100 mg QD). The C max and AUC of (S)-methadone increased by 65% (90% CI: 53%, 79%) and 103% (90% CI: 85%, 124%), respectively. Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed (see PRECAUTIONS - Drug Interactions).Tacrolimus (CYP3A4 substrate): Repeat oral dose administration of voriconazole (400 mgQ12h x 1 day, then 200 mg Q12h x 6 days) increased tacrolimus (0.1 mg/kg single dose) C max and AUCτ in healthy subjects by an average of 2-fold (90% CI: 1.9, 2.5) and 3-fold (90% CI: 2.7, 3.8), respectively. When initiating therapy with voriconazole in patients already receiving tacrolimus, it is recommended that the tacrolimus dose be reduced to one-third of the original dose and followed with frequent monitoring of the tacrolimus blood levels. Increased tacrolimus levels have been associated with nephrotoxicity. When voriconazole is discontinued, tacrolimus levels should be carefully monitored and the dose increased as necessary (see PRECAUTIONS - Drug Interactions).Warfarin (CYP2C9 substrate): Coadministration of voriconazole (300 mg Q12h x 12 days) with warfarin (30 mg single dose) significantly increased maximum prothrombin time by approximately 2 times that of placebo in healthy subjects. Close monitoring of prothrombin time or other suitable anticoagulation tests is recommended if warfarin and voriconazole are coadministered and the warfarin dose adjusted accordingly (see PRECAUTIONS - Drug Interactions).Oral Coumarin Anticoagulants (CYP2C9, CYP3A4 substrates): Although not studied in vitro or in vivo, voriconazole may increase the plasma concentrations of coumarin anticoagulants and therefore may cause an increase in prothrombin time. If patients receiving coumarin preparations are treated simultaneously with voriconazole, the prothrombin time or other suitable anti-coagulation tests should be monitored at close intervals and the dosage of anticoagulants adjusted accordingly (see PRECAUTIONS - Drug Interactions).Statins (CYP3A4 substrates): Although not studied clinically, voriconazole has been shown to inhibit lovastatin metabolism in vitro (human liver microsomes). Therefore, voriconazole is likely to increase the plasma concentrations of statins that are metabolized by CYP3A4. It is recommended that dose adjustment of the statin be considered during coadministration. Increased statin concentrations in plasma have been associated with rhabdomyolysis (see PRECAUTIONS - Drug Interactions).Benzodiazepines (CYP3A4 substrates): Although not studied clinically, voriconazole has been shown to inhibit midazolam metabolism in vitro (human liver microsomes). Therefore, voriconazole is likely to increase the plasma concentrations of benzodiazepines that are metabolized by CYP3A4 (e.g., midazolam, triazolam, and alprazolam) and lead to a prolongedsedative effect. It is recommended that dose adjustment of the benzodiazepine be considered during coadministration (see PRECAUTIONS - Drug Interactions).Calcium Channel Blockers (CYP3A4 substrates): Although not studied clinically, voriconazole has been shown to inhibit felodipine metabolism in vitro (human liver microsomes). Therefore, voriconazole may increase the plasma concentrations of calcium channel blockers that are metabolized by CYP3A4. Frequent monitoring for adverse events and toxicity related to calcium channel blockers is recommended during coadministration. Dose adjustment of the calcium channel blocker may be needed (see PRECAUTIONS - Drug Interactions).Sulfonylureas (CYP2C9 substrates): Although not studied in vitro or in vivo, voriconazole may increase plasma concentrations of sulfonylureas (e.g., tolbutamide, glipizide, and glyburide) and therefore cause hypoglycemia. Frequent monitoring of blood glucose and appropriate adjustment (i.e., reduction) of the sulfonylurea dosage is recommended during coadministration (see PRECAUTIONS - Drug Interactions).Vinca Alkaloids (CYP3A4 substrates): Although not studied in vitro or in vivo, voriconazole may increase the plasma concentrations of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to neurotoxicity. Therefore, it is recommended that dose adjustment of the vinca alkaloid be considered.No significant pharmacokinetic interactions were observed when voriconazole was coadministered with the following agents. Therefore, no dosage adjustment for these agents is recommended:Prednisolone (CYP3A4 substrate): Voriconazole (200 mg Q12h x 30 days) increased C max and AUC of prednisolone (60 mg single dose) by an average of 11% and 34%, respectively, in healthy subjects.Digoxin (P-glycoprotein mediated transport): Voriconazole (200 mg Q12h x 12 days) had no significant effect on steady state C max and AUCτ of digoxin (0.25 mg once daily for 10 days) in healthy subjects.Mycophenolic acid (UDP-glucuronyl transferase substrate): Voriconazole (200 mg Q12h x 5 days) had no significant effect on the C max and AUCτof mycophenolic acid and its major metabolite, mycophenolic acid glucuronide after administration of a 1 g single oral dose of mycophenolate mofetil.Two-Way InteractionsConcomitant use of the following agents with voriconazole is contraindicated:Rifabutin (potent CYP450 inducer): Rifabutin (300 mg once daily) decreased the C max and AUCτof voriconazole at 200 mg twice daily by an average of 67% (90% CI: 58%, 73%) and 79% (90% CI: 71%, 84%), respectively, in healthy subjects. During coadministration with rifabutin (300 mg once daily), the steady state C max and AUCτof voriconazole following an increased dose of 400 mg twice daily were on average approximately 2 times higher, compared。
原研专利药品
注射用头孢米诺钠 注射用头孢孟多酯钠 苯磺酸左旋氨氯地平片 盐酸氨溴索片 美洛昔康注射液 美洛昔康片 替米沙坦片 盐酸氨溴索注射液 吲达帕胺缓释片 盐酸曲美他嗪片(薄膜衣) 碘比醇注射液 曲司氯铵片(糖衣) 氧氟沙星滴眼液 氧氟沙星眼膏 注射用盐酸博莱霉素(冻干) 盐酸托莫西汀胶囊 头孢特仑新戊酯片(薄膜衣) 吡美莫司乳膏 苹果酸舒尼替尼胶囊 注射用盐酸伊达比星(冻干) 依托考昔片(薄膜衣) 盐酸左布比卡因注射液 盐酸度洛西汀肠溶胶囊 注射用盐酸万古霉素 盐酸托烷司琼注射液 利奈唑胺片(薄膜衣) 利奈唑胺注射液 碘佛醇注射液 注射用盐酸头孢甲肟 阿立哌唑片 瑞巴派特片(薄膜衣) 盐酸丙卡特罗片 环孢素注射液 唑来膦酸注射液 注射用厄他培南(冻干) 孟鲁司特钠颗粒 磷酸西格列汀片(薄膜衣) 注射用醋酸卡泊芬净 卡前列素氨丁三醇注射液
注射用头孢呋辛钠 异氟烷 恩氟烷 克拉霉素片厂 匈牙利吉瑞大药厂 匈牙利吉瑞大药厂 意大利辉瑞制药厂Pfizer Italia SRL 意大利辉瑞制药厂Pfizer Italia SRL 澳大利亚Pfizer (Perth) Pty Limited 德国 MEDA Manufacturing GmbH 日本协和发酵工业株式会社富士工厂 波多黎各Baxter Healthcare of Puerto 地氟烷液 Rico 日本中外制药株式会社宇都宫工厂Utsunomiya 注射用重组人粒细胞刺激因子 Plant of Chugai Pharma Manufacturing Co., (CHO细胞)(冻干) Ltd. 德国勃林格殷格翰国际公司Boehringer 瑞格列奈片 Ingelheim 注射用伏立康唑 爱尔兰Pfizer Irland Pharmceuticals Limited 盐酸普罗帕酮片(薄膜衣) 德国Abbott,Gmbh&Co.KG 盐酸维拉帕米缓释片 德国Abbott,Gmbh&Co.KG 精蛋白锌重组人胰岛素注射液 埃及礼来 重组人胰岛素注射液 埃及礼来 精蛋白锌重组人胰岛素混合注射 埃及礼来 注射用培美曲塞二钠(冻干) 法国礼来Lilly France S.A.S. 注射用盐酸吉西他滨(冻干) 法国礼来Lilly France S.A.S. 日本兴和株式会社(Kowa Company, Ltd., 匹伐他汀钙片(薄膜衣) Nagoya Factory) 紫杉醇注射液 意大利Bristol Myers Squibb SRL 德国勃林格殷格翰国际公司Boehringer 噻托溴铵粉吸入剂 Ingelheim 德国勃林格殷格翰国际公司Boehringer 盐酸普拉克索片 Ingelheim 吸入用复方异丙托溴铵溶液 英国勃林格殷格翰 吸入用异丙托溴铵溶液 英国勃林格殷格翰 硫酸氨基葡萄糖胶囊 爱尔兰罗达药厂(Rottapharm Ltd) 硫酸氨基葡萄糖散 爱尔兰罗达药厂(Rottapharm Ltd) 法国施维雅药厂Les Laboratoires Servier 吲达帕胺片(薄膜衣) Industrie 甲磺酸吉米沙星片(薄膜衣) 韩国LG Life Sciences, Ltd. 培哚普利片 施维雅(天津)制药有限公司 噻奈普汀钠片(糖衣) 施维雅(天津)制药有限公司 日本参天制药株式会社能登工厂Santen 左氧氟沙星滴眼液 Pharmaceutical Co.,Ltd. Noto Plant(参天制 药(中国)有限公司分装) 拉莫三嗪片 英国葛兰素史克有限公司 拉西地平片(薄膜衣) 西班牙葛兰素 拉米夫定片(薄膜衣) 葛兰素史克制药(苏州)有限公司 丙酸氟替卡松鼻喷雾剂 西班牙葛兰素 吸入用硫酸沙丁胺醇溶液 英国葛兰素史克有限公司 沙美特罗替卡松粉吸入剂 英国葛兰素史克有限公司 二甲双胍马来酸罗格列酮片(薄膜 西班牙葛兰素 衣) 注射用盐酸托泊替康(冻干) 意大利GlaxoSmithKline Manufacturing S.p.A. 磺达肝癸钠注射液 法国Glaxo Wellcome Production 阿莫西林克拉维酸钾干混悬剂 英国葛兰素史克有限公司
纷享销客组织架构模拟真是企业
纷享销客组织架构模拟真是企业纷享销客是一家拥有真实企业模拟的组织，其组织架构涵盖了各个部门和职能，以保证企业的正常运营和发展。
下面是一个模拟真实企业的纷享销客的组织架构，以便更好地理解其运作方式。
1.高级管理层：- 首席执行官（Chief Executive Officer，CEO）：负责全面领导和管理公司，做出战略决策，并对整个公司的业绩负责。
- 首席运营官（Chief Operating Officer，COO）：负责公司的日常运营，包括生产、供应链、项目管理等。
- 首席财务官（Chief Financial Officer，CFO）：负责财务管理和战略规划，包括财务报表、预算、融资等。
- 首席技术官（Chief Technology Officer，CTO）：负责技术战略和产品研发，以保持公司的技术竞争力。
- 首席市场官（Chief Marketing Officer，CMO）：负责市场营销策略和品牌推广，以提高公司的市场份额和知名度。
2.营销部门：-销售团队：负责推销公司的产品和服务，与客户进行协商和洽谈。
-市场营销团队：负责市场调查、竞争分析、品牌推广等市场策略。
-客户服务团队：负责与客户进行沟通和关系维护，解答客户的问题和需求。
3.技术部门：-研发团队：负责开发和改进公司的产品和服务，保证其技术优势和竞争力。
-IT团队：负责公司的信息技术基础设施，包括网络、服务器、数据存储等。
-数据科学团队：负责数据分析和挖掘，为公司的决策提供数据支持。
4.运营部门：-供应链团队：负责物流管理、采购和库存控制，保证产品正常供应。
- 项目管理办公室（Project Management Office，PMO）：负责项目的规划、执行和监控。
5.财务部门：-会计团队：负责公司的财务报表和账务记录，确保公司的财务合规性。
-财务规划分析团队：负责预测和规划公司的财务状况，为管理层提供决策支持。
6.人力资源部门：-人力资源团队：负责员工招聘、培训和福利管理，维护人力资源的稳定和发展。